 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Efficacy and safety of the combination of pabocinil, pembrolizumab and letrozole in the treatment of HR+ metastatic breast cancer

Eur J Cancer: Efficacy and safety of the combination of pabocinil, pembrolizumab and letrozole in the treatment of HR+ metastatic breast cancer

 Last Update: 2021-08-02
 Source: Internet
 Author: User

Tags

msi cancer

aromatase inhibitors supplements

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CDK4/6 inhibitors (CDK4/6i) can prevent the transition of the cell cycle from G1 to S phase and show promise in overcoming endocrine resistance

Breast cancer

CDK4/6 inhibitors can regulate the immune response of breast cancer

Immunization Eur J Cancer Eur J Cancer

Patients with stage IV HR+HER2-metastatic breast cancer were recruited and treated with pabocinil, pembrolizumab, and letrozole

From November 2016 to July 2020, a total of 23 patients were recruited, of which 20 were available for reactivity assessment, of which 4 were in cohort 1 and 16 were in cohort 2

Grade 3-4 adverse reactions are neutropenia (83%), leukopenia (65%), thrombocytopenia (17%) and elevated liver enzymes (17%)

PFS and OS in 2 cohorts

In cohort 1, 50% of patients achieved partial remission (PR), and 50% of patients had stable disease (SD)

In the 2 cohorts, 31% of patients achieved complete remission (CR), 25% of patients achieved PR, and 31% of patients achieved SD

In summary, the combination of Pabocinib , pembrolizumab, and letrozole is well tolerated in patients with HR+ metastatic breast cancer, and the complete remission rate can be as high as 31%

The combined regimen of Pabocinil, Pembrolizumab and Letrozole is well tolerated in patients with HR+ metastatic breast cancer, and the complete remission rate can be as high as 31%.

Original source:

Yuan Yuan,Lee Jin Sun,Yost Susan E et al.

Phase I / II trial of palbociclib, pembrolizumab? And letrozole in patients with hormone receptor-positive metastatic breast cancer

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.